Starling Oncology, Inc. STLN
$6.90
$0.274.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.79M | -2.49M | -7.51M | -16.50M | -17.01M |
| Total Depreciation and Amortization | 1.84M | 1.62M | 1.63M | 1.72M | 1.81M |
| Total Amortization of Deferred Charges | 1.26M | 1.21M | 1.21M | 1.17M | 1.13M |
| Total Other Non-Cash Items | 4.34M | -3.48M | 251.00K | 7.15M | 7.16M |
| Change in Net Operating Assets | 14.30M | 928.00K | 7.65M | -6.17M | -3.29M |
| Cash from Operations | 11.94M | -2.22M | 3.23M | -12.63M | -10.20M |
| Capital Expenditure | -908.00K | -1.04M | -1.06M | -604.00K | -1.21M |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -908.00K | -1.04M | -1.06M | -604.00K | -1.21M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -308.00K | -269.00K | -309.00K | -243.00K | -240.00K |
| Issuance of Common Stock | 90.00K | 241.00K | 4.09M | 10.84M | 2.20M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -50.00K | -- | -- |
| Cash from Financing | -218.00K | -28.00K | 3.73M | 10.60M | 1.96M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.81M | -3.29M | 5.91M | -2.63M | -9.45M |